- Latest available (Revised)
- Original (As made)
This is the original version (as it was originally made). This item of legislation is currently only available in its original format.
Order made by the Secretary of State under section 6(1) of the Export Control Act 2002, laid before Parliament under section 13(2) of that Act, for approval by resolution of each House of Parliament within forty days beginning with the day on which the Order was made, subject to extension for periods of dissolution, prorogation or adjournment for more than four days.
Statutory Instruments
Customs
Made
29th November 2010
Laid before Parliament
29th November 2010
Coming into force
30th November 2010
The Secretary of State, in exercise of the powers conferred by sections 1, 6 and 7 of the Export Control Act 2002(1), makes the following Order:
1.—(1) This Order may be cited as the Export Control (Amendment) (No.3) Order 2010.
(2) It comes into force on 30th November 2010.
(3) It ceases to have effect on 28th November 2011.
2.—(1) The Export Control Order 2008(2) is amended as follows.
(2) After Article 4 insert—
4A.—(1) Subject to articles 17 and 26, no person shall export pharmaceutical goods for human use containing the active ingredient thiopental sodium if paragraph (2) or (3) applies.
(2) This paragraph applies where the destination is the United States of America.
(3) This paragraph applies where the destination is not the United States of America but the exporter knows that the final destination of the goods is the United States of America.”.
(3) In article 17 (transit or transhipment exception), in sub-paragraph (1) after “4,” insert “4A,”.
(4) In paragraphs (1)(a)(i) and (2)(a) of article 41 (application of CEMA in respect of offences), after “4,” insert “4A,”.
Mark Prisk
Minister of State for Business Enterprise
Department for Business, Innovation and Skills
29th November 2010
(This note is not part of the Order)
This Order amends the Export Control Order 2008 (S.I. 2008/3231). Article 2 introduces a new control on the export of pharmaceutical goods for human use containing the active ingredient thiopental sodium to the United States of America and makes other related amendments. This Order will cease to have effect on 28 November 2011.
The Explanatory Memorandum is available alongside the instrument on the OPSI website. The Impact Assessment is currently being prepared.
S.I. 2008/3231; relevant amending instruments are S.I. 2009/1852 and S.I. 2010/121.
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: